| Marriott and Bridges from School to Work for Youth with Disabilities - Video NFL Legend Terry Bradshaw to Speak at 20th Anniversary Fundraising Gala Tonight feedproxy.google.com |
Charles River's WuXi Acquisition Axed, Trius Fails to Debut: Biotech Deals That Didn’t Happen The Burrill Report submits: By Marie DaghlianThe biggest deals news of the week were the deals that didn’t happen. Charles River Laboratories (CRL) called off its $1.6 billion deal to buy WuXi PharmaTech (WX) due to investor opposition led by Jana Partners, its largest shareholder (see story). And, two life sciences companies failed to complete their expected initial public offerings, as investors showed little interest in unprofitable companies. Complete Story » seekingalpha.com |
Why Cumberland Pharma Needs Acetadote Approval to Avert Disaster Rockford Coscia submits:January 23, 2011 is approaching Cumberland Pharmaceuticals (CPIX) like a iceberg, threatening to sink revenues almost entirely for the small Tennessee biotech. On that date, the comapany’s primary revenue generator, Acetadote, will face generic competition. The company has been frantically trying to replace or extend the revenue of its star product; so far with little success.One such way that Cumberland hopes to avert disaster is with a potential Acetadote FDA approval for non-acetaminophen acute liver failure. Acetadote is already approved for acetominophen-related acute liver failure and the company hopes to extend it to non-acetaminophen liver failure as well. Acetadote for this indication was granted priority review and the company expects a response by the scheduled September 10 PDUFA date. Along with approval for the new indication, Cumberland has asked for additional market exclusivity for its Acetadote product. While Cumberland stands a good chance to gain approval for the new indication, the potential market exclusivity agreement remains murky.Complete Story » seekingalpha.com |
What Most Alkerme Investors Really Want M.E. Garza submits: By Patrick Crutcher Alkermes Inc. (NASDAQ:ALKS) has already received news from the FDA that they had approved their sNDA of Vivitrol for Prevention of Relapse to Opioid Dependence. This comes after unanimous support for Vivitrol during their FDA advisory panel back in mid-September. More importantly, there also appears to be excitement in the medical community for the new treatment option.Complete Story » seekingalpha.com |
Back to Sports after ACL Injury - Video Young Female Athletes Prone to Career-Ending Knee Injuries feedproxy.google.com |